Last reviewed · How we verify
ferric hydroxide polymaltose complex
At a glance
| Generic name | ferric hydroxide polymaltose complex |
|---|---|
| Sponsor | Ain Shams University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Alternate-day Versus Daily Oral Iron Therapy in Children With Iron Deficiency Anaemia (PHASE4)
- EFFICACY OF IV VERSUS ORAL IRON IN THE TREATMENT OF IRON DEFICIENCY ANEMIA DURING PREGNANCY (PHASE1)
- Hypoferritinemia Without Anemia Among Reproductive Age Females (NA)
- Comparison Of Efficacy Of Iron Polymaltose Complex And Ferrous Sulphate In Iron Deficiency Anemia In Pediatric Patients (NA)
- Daily Versus Alternate Day Regimen of Iron Supplementation in Children with Iron Deficiency Anemia (PHASE4)
- Effects of Enhancers and Inhibitors on Absorption From Iron Supplements (NA)
- Evaluation on Performance and Oxydative Stress in Patient With Iron deficIency and Stable Heart Failure Study (PHASE4)
- Iron Supplementation for Acute Anemia After Postbariatric Abdominoplasty (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ferric hydroxide polymaltose complex CI brief — competitive landscape report
- ferric hydroxide polymaltose complex updates RSS · CI watch RSS
- Ain Shams University portfolio CI